Development of a Novel Enzyme-Linked Immunosorbent Assay and Lateral Flow Test System for Improved Serodiagnosis of Visceral Leishmaniasis in Different Areas of Endemicity

Development of a Novel Enzyme-Linked Immunosorbent Assay and Lateral Flow Test System for Improved Serodiagnosis of Visceral Leishmaniasis in Different Areas of Endemicity

Visceral leishmaniasis (VL) is caused by protozoan parasites of the Leishmania donovani complex and is one of the most prominent vector-borne infectious diseases with epidemic and mortality potential if not correctly diagnosed and treated. East African countries suffer from a very high incidence...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Mahdavi, Rouzbeh, Shams-Eldin, Hosam, Witt, Sandra, Latz, Andreas, Heinz, Daniela, Fresco-Taboada, Alba, Aira, Cristina, Hübner, Marc P., Sukyte, Dalia, Visekruna, Alexander, Teixeira, Henrique C., Abass, Elfadil, Steinhoff, Ulrich
Formatua: Artikulua
Hizkuntza:ingelesa
Argitaratua: Philipps-Universität Marburg 2023
Gaiak:
visceral leishmaniasis
lateral flow assay, ELISA
improved kinesin antigen
VL in East Africa
serodiagnosis
Medizin
Medical sciences Medicine
Sarrera elektronikoa:PDF testu osoa
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
Deskribapena
Gaia:Visceral leishmaniasis (VL) is caused by protozoan parasites of the Leishmania donovani complex and is one of the most prominent vector-borne infectious diseases with epidemic and mortality potential if not correctly diagnosed and treated. East African countries suffer from a very high incidence of VL, and although several diagnostic tests are available for VL, diagnosis continues to represent a big challenge in these countries due to the lack of sensitivity and specificity of current serological tools. Based on bioinformatic analysis, a new recombinant kinesin antigen from Leishmania infantum (rKLi8.3) was developed. The diagnostic performance of rKLi8.3 was evaluated by enzyme-linked immunosorbent assay (ELISA) and lateral flow test (LFT) on a panel of sera from Sudanese, Indian, and South American patients diagnosed with VL or other diseases, including tuberculosis, malaria, and trypanosomiasis. The diagnostic accuracy of rKLi8.3 was compared with rK39 and rKLO8 antigens. The VL-specific sensitivity of rK39, rKLO8, and rKLi8.3 ranged from 91.2% over 92.4% to 97.1% and specificity ranged from 93.6% over 97.6% to 99.2%, respectively. In India, all tests showed a comparable specificity of 90.9%, while the sensitivity ranged from 94.7% to 100% (rKLi8.3). In contrast to commercial serodiagnostic tests, rKLi8.3-based ELISA and LFT showed improved sensitivity and no cross-reactivity with other parasitic diseases. Thus, rKLi8.3-based ELISA and LFT offer improved VL serodiagnostic efficiency in East Africa and other areas of endemicity.
Alearen deskribapena:Gefördert durch den Open-Access-Publikationsfonds der UB Marburg.
DOI:10.1128/spectrum.04338-22

Antzeko izenburuak